Joshua Bauml, MD, an assistant professor at Perelman School of Medicine at the University of Pennsylvania, discusses the possibilities with using liquid biopsies in patients with lung cancer.
Joshua Bauml, MD, an assistant professor at Perelman School of Medicine at the University of Pennsylvania, discusses the possibilities with using liquid biopsies in patients with lung cancer.
By using liquid biopsies, it may be possible to assess tumor mutation burden, which is a major problem with immunotherapy in lung cancer, Bauml says. A study published inNaturealso looked at liquid biopsies in patients with lung cancer and discovered a potential approach to predicting relapse based on when circulating tumor DNA (ctDNA) appears.
Bauml suggests that liquid biopsies can also be used to monitor patients and would be more efficient than typical scans. The blood test results from a liquid biopsy can provide a visual image of the genetic landscape in each patient. This could ultimately help doctors see exactly how the patient is reacting to whichever therapy they are receiving.
Phase 3 CheckMate -73L of Nivolumab/Ipilimumab in NSCLC Misses PFS End Point
May 13th 2024Nivolumab with ipilimumab did not lead to progression-free survival benefits in patients with unresectable stage III non-small cell lung cancer, missing the primary end point of the CheckMate -73L study.
Read More
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More